Global Cell & Gene Therapy Manufacturing Services Market Overview
According to SPER Market Research, the Global Cell & Gene Therapy Manufacturing Services Market is estimated to reach USD 26.11 billion by 2032 with a CAGR of 17.74%.
Cell treatment and gene therapy are the two primary product categories in cell and gene therapies. By regenerating or altering particular cell types, or by giving cells to deliver therapy across the body, cell therapy tries to treat ailments and diseases. When using cell therapy, the patient's cells are first created or altered outside of the body. The cells may come from a donor or the patient. In vivo (in the body) or ex vivo (outside the body), gene therapy replaces or introduces genes into cells to treat diseases (ex vivo). The market is expanding as a result of rising rates of cancer and other target diseases as well as rising R&D expenditures by pharmaceutical companies.
Impact of COVID-19 on the Global Cell & Gene Therapy Manufacturing Services Market
The market for manufacturing services for cell and gene therapies suffered during the COVID-19 pandemic. The government-imposed running capacity restrictions and the disruption of the supply chain and logistical systems were the two main causes of this. The United States Food and Drug Administration's Coronavirus Treatment Acceleration Program (CTAP) 2020 states that COVID-19-related therapies include cell therapy products, such as cellular immunotherapies and other kinds of autologous and allogeneic cells, like stem cells, and associated goods. As a result, the need for manufacturing services rises as a result of the treatment of COVID-19 with cell therapy products, which is anticipated to have a major impact on market growth. Additionally, the US Food and Drug Administration (FDA) authorised BioCardia to begin a Phase I/II clinical trial of COVID-19 stem cell therapy, BCDA-04, in adults recovering from COVID-19-related acute respiratory distress syndrome (ARDS). These new IND applications for treating COVID-19 will encourage more businesses to use contract manufacturing services.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Therapy Type, By Scale, By Mode, By Workflow.
|
| Regions covered | Asia-Pacific, Europe, Middle East and Africa, North America, Latin America
|
| Companies Covered | Bluebird Bio Inc., Boehringer Ingelheim, Catalent Inc., Cellular Therapeutics, F. Hoffmann-La Roche Ltd, Hitachi Chemical Co. Ltd., Lonza, Merck KGaA, Miltenyi Biotec, Novartis AG, Samsung Biologics, Takara Bio Inc., Thermo Fisher Scientific, Wuxi Advanced Therapies.
|
Global Cell & Gene Therapy Manufacturing Services Market Segmentation:
1. By Therapy Type:
- Cell Therapy Manufacturing
- Gene Therapy Manufacturing
2. By Scale:
- Pre-commercial/ R&D Manufacturing
- Commercial Scale Manufacturing
3. By Mode:
- Contract Manufacturing
- In-house Manufacturing
4. By Workflow:
- Cell Processing
- Cell Banking
- Process Development
- Fill & Finish Operations
- Analytical And Quality Testing
5. By Region:
- Asia-Pacific
- Europe
- Middle East
- Africa
- North America
- Latin America
Key Topics Covered in the Report:
- Global Cell & Gene Therapy Manufacturing Services Market Size (FY’2019-FY’2032)
- Overview of Global Cell & Gene Therapy Manufacturing Services Market
- Segmentation of Global Cell & Gene Therapy Manufacturing Services Market By Therapy Type {Cell Therapy Manufacturing (Stem Cell Therapy, Non-Stem Cell Therapy), Gene Therapy Manufacturing}
- Segmentation of Global Cell & Gene Therapy Manufacturing Services Market By Workflow (Cell Processing, Cell Banking, Process Development, Fill & Finish Operations, Analytical and Quality Testing, Raw Material Testing, Vector Production, Other Workflow)
- Statistical Snap of Global Cell & Gene Therapy Manufacturing Services Market
- Growth Analysis of Global Cell & Gene Therapy Manufacturing Services Market
- Problems and Challenges in Global Cell & Gene Therapy Manufacturing Services Market
- Competitive Landscape in the Global Cell & Gene Therapy Manufacturing Services Market
- Impact of COVID-19 and Demonetization on Global Cell & Gene Therapy Manufacturing Services Market
- Competitive Analysis of Global Cell & Gene Therapy Manufacturing Services Market
- Major Players in the Global Cell & Gene Therapy Manufacturing Services Market
- SWOT Analysis of Global Cell & Gene Therapy Manufacturing Services Market
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Cell & Gene Therapy Manufacturing Services Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Competitive Landscape
6.1 Global Cell & Gene Therapy Manufacturing Services Manufacturing Base Distribution, Sales Area, Product Type
6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cell & Gene Therapy Manufacturing Services Market
7. Global Cell & Gene Therapy Manufacturing Services Market, By Therapy Type, 2019-2032 (USD Million)
7.1. Cell Therapy Manufacturing
7.1.1. Stem Cell Therapy
7.1.2. Non-Stem Cell Therapy
7.2. Gene Therapy Manufacturing
8. Global Cell & Gene Therapy Manufacturing Services Market, By Scale, 2019-2032 (USD Million)
8.1. Pre-commercial/ R&D Manufacturing
8.2. Commercial Scale Manufacturing
9. Global Cell & Gene Therapy Manufacturing Services Market, By Mode, 2019-2032 (USD Million)
9.1. Contract Manufacturing
9.2. In-house Manufacturing
10. Global Cell & Gene Therapy Manufacturing Services Market, By Workflow, 2019-2032 (USD Million)
10.1. Cell Processing
10.2. Cell Banking
10.3. Process Development
10.4. Fill & Finish Operations
10.5. Analytical And Quality Testing
10.6. Raw Material Testing
10.7. Vector Production
10.8. Other Workflow
11. Global Cell & Gene Therapy Manufacturing Services Market, By Region, 2019-2032 (USD Million)
11.1. Global Cell & Gene Therapy Manufacturing Services Market Size and Market Share by Region (2019-2025)
11.2. Global Cell & Gene Therapy Manufacturing Services Market Size and Market Share by Region (2026-2032)
11.3. Asia-Pacific
11.3.1. Australia
11.3.2. China
11.3.3. India
11.3.4. Japan
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4. Europe
11.4.1. France
11.4.2. Germany
11.4.3. Italy
11.4.4. Spain
11.4.5. United Kingdom
11.4.6. Rest of Europe
11.5. Middle East and Africa
11.5.1. Kingdom of Saudi Arabia
11.5.2. United Arab Emirates
11.5.3. Rest of Middle East & Africa
11.6. North America
11.6.1. Canada
11.6.2. Mexico
11.6.3. United States
11.7. Latin America
11.7.1. Argentina
11.7.2. Brazil
11.7.3. Rest of Latin America
12. Company Profiles
12.1. Bluebird Bio Inc.
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Boehringer Ingelheim
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Catalent Inc.
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. Cellular Therapeutics
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. F. Hoffmann-La Roche Ltd
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Hitachi Chemical Co. Ltd.
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Lonza
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Merck KGaA
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Miltenyi Biotec
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Novartis AG
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Samsung Biologics
12.11.1. Company details
12.11.2. Financial outlook
12.11.3. Product summary
12.11.4. Recent developments
12.12. Takara Bio Inc.
12.12.1. Company details
12.12.2. Financial outlook
12.12.3. Product summary
12.12.4. Recent developments
12.13. Thermo Fisher Scientific
12.13.1. Company details
12.13.2. Financial outlook
12.13.3. Product summary
12.13.4. Recent developments
12.14. Wuxi Advanced Therapies
12.14.1. Company details
12.14.2. Financial outlook
12.14.3. Product summary
12.14.4. Recent developments
13. List of Abbreviations
14. Reference Links
15. Conclusion
16. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
